Proroxan hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 593122

CAS#: 33025-33-1

Description: Proroxan hydrochloride is a Anti-Adrenergic (alpha-Receptor) agent.

Chemical Structure

img
Proroxan hydrochloride
CAS# 33025-33-1
Instruction

Theoretical Analysis

MedKoo Cat#: 593122
Name: Proroxan hydrochloride
CAS#: 33025-33-1
Chemical Formula: C21H24ClNO3
Exact Mass: 373.14
Molecular Weight: 373.880
Elemental Analysis: C, 67.46; H, 6.47; Cl, 9.48; N, 3.75; O, 12.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Proroxan hydrochloride; AY-24,269; AY 24,269; AY24,269

IUPAC/Chemical Name: 1,4-Benzodioxan, 6-(3-(3-phenylpyrrolidinyl)propionyl)-, hydrochloride

InChi Key: QQZPGRDQMBPRFY-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H23NO3.ClH/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16;/h1-7,14,18H,8-13,15H2;1H

SMILES Code: O=C(C1=CC=C(OCCO2)C2=C1)CCN3CC(C4=CC=CC=C4)CC3.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 373.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kundashev UK, Salenko YA, Morozov IS, Zurdinov AZ, Barchukov VG. [EFFECT OF MEDIATOR-TYPE DRUGS ON HUMAN PSYCHOPHYSIOLOGICAL STATUS DURING MODEL OPERATOR ACTIVITY]. Eksp Klin Farmakol. 2016;79(2):9-13. Russian. PubMed PMID: 27416676.

2: Ivanov IV, Bondarenko RA. [INDIVIDUAL APPROACH TO THE USE OF MEDICATIONS TO NORMALIZE SITUATIONAL ANXIETY UNDER THE PSYCHO-EMOTIONAL STRESS]. Aviakosm Ekolog Med. 2015;49(2):32-5. Russian. PubMed PMID: 26087584.

3: Ianchuk PI, Prykhod'ko TP, Pasichnichenko OM, Tieriekhov AA, Tsybenko VO. [Mechanisms of contractile action of acetylcholine on hepatic veins]. Fiziol Zh. 2011;57(1):21-8. Ukrainian. PubMed PMID: 21516830.

4: Grashin RA, Antonov VG, Karpishchenko AI, Khaĭrutdinov VR. [The free radical oxidation and antioxidant defense systems as indicators of the activity of keratinocytic proliferation in psoriasis]. Klin Lab Diagn. 2010 Jan;(1):18-24. Russian. PubMed PMID: 20205333.

5: Shabanov PD, Anokhin AG. [Evaluation of anti-seasick properties of pyrroxan and dimenhydrinate under conditions of maximal and submaximal statokinetic load in humans]. Eksp Klin Farmakol. 2005 May-Jun;68(3):50-5. Russian. PubMed PMID: 16047682.

6: Vasin MV, Ushakov IB, Koroleva LV, Lairov IA, Radchenko SN. In vitro response of mitochondrial succinate oxidase system to epinephrine in human blood lymphocytes from health individuals and patients with neurocirculatory dystonia. Bull Exp Biol Med. 2002 Oct;134(4):393-6. PubMed PMID: 12533769.

7: Morozov IS, Vetliaeva OA, Barchukov VG, Salenko IuA. [Operator activity and changes in the functional state of central adrenergic systems (a neurophysiological study)]. Eksp Klin Farmakol. 2001 Jul-Aug;64(4):13-6. Russian. PubMed PMID: 11589100.

8: Lomov IuM, Kharlanova NG, Bardakhch'ian EA. [The effect of adrenoblockers on the ultrastructural changes in the epithelium and neural elements of the small intestine of suckling rabbits with experimental cholera]. Arkh Patol. 1996 Nov-Dec;58(6):51-5. Russian. PubMed PMID: 9139594.

9: Sledkov AI, Bernarskii KV, Shilina MN. [Involvement of adrenergic mechanisms in developing the nervous syndrome of high pressure and nitrogen narcosis]. Aviakosm Ekolog Med. 1996;30(5):28-33. Russian. PubMed PMID: 8974595.

10: Bulekbaeva DE, Khanturin MR, Lakpaeva ShG. [The mechanisms of adrenergic and cholinergic effects on the lymphatic vessels of reptiles]. Fiziol Zh Im I M Sechenova. 1993 Oct;79(10):55-9. Russian. PubMed PMID: 7909473.

11: Bulekbaeva LE, Nurgalieva KB, Demchenko GA. [The characteristics of the adrenergic mechanisms regulating the lymph flow in arterial hypertension in dogs]. Fiziol Zh SSSR Im I M Sechenova. 1991 Sep;77(9):245-9. Russian. PubMed PMID: 1687134.

12: Aliev KO. [A voltametric study of the role of the noradrenaline innervation of the hippocampus in cats in paradoxical sleep]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1990 Jul-Aug;40(4):714-20. Russian. PubMed PMID: 1979197.

13: Nazarov IP, Ianitskiĭ AV, Peterson RR, Popov AA. [Adrenoganglioplegia as a method of correction of hemodynamic disorders in surgical patients with initial hypotension]. Vestn Khir Im I I Grek. 1990 Apr;144(4):93-7. Russian. PubMed PMID: 1978430.

14: Kaĭfadzhian MA, Dzhanpoladian EG. [The Ca2+ reactivity and the subunit composition of myocardial actomyosin during the pyromecaine and pyrroxan treatment of experimental ischemia]. Farmakol Toksikol. 1990 Jan-Feb;53(1):27-30. Russian. PubMed PMID: 1970309.

15: Lobzin IuV, Gnoevoĭ VB, Mosichev IuN, Galemshin AA. [Clinico-psychophysiologic evaluation of the effect of pirroksan on the recovery of work capacity in sailors having had viral hepatitis A]. Voen Med Zh. 1989 Nov;(11):55-6. Russian. PubMed PMID: 2617918.

16: Shepotinovskiĭ VI, Rogozniaia NA, Mikashinovich ZI. [Digestive enzyme activity during immobilization stress and its pharmacologic correction with adrenoblockaders]. Patol Fiziol Eksp Ter. 1989 Nov-Dec;(6):49-52. Russian. PubMed PMID: 2576468.

17: Shepotinovskiĭ VI, Mikashinovich ZI, Shapiro GA, Ivanova OV. [Functional biochemical changes and their pharmacologic correction by pirroksan in renal ischemia]. Patol Fiziol Eksp Ter. 1989 Jul-Aug;(4):24-7. Russian. PubMed PMID: 2574439.

18: Lelevich VV, Pron'ko PS, Liopo AV, Deniskovets AA. [Effect of drugs possessing antialcoholic activity on ethanol pharmacokinetics]. Farmakol Toksikol. 1989 Jul-Aug;52(4):85-8. Russian. PubMed PMID: 2572455.

19: Dzhanpoladian EG, Karagezian KG, Sambelian VM, Aloian GA. [Effect of anti-angina therapy on phospholipid levels of the myocardium in ischemic lesions]. Kardiologiia. 1988 Oct;28(10):88-90. Russian. PubMed PMID: 3147341.

20: Korovin KF, Kovalev OA, Iampol'skaia LI, Samokhin GS. [Aldosterone content of the blood and tissues in rats with an altered level of adrenergic activity]. Probl Endokrinol (Mosk). 1988 Mar-Apr;34(2):62-4. Russian. PubMed PMID: 2839821.